Conference call to discuss developing treatments for Ataxia-Telangiectasia (A-T) to be held on January 7 hosted by Citizens.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital
- Quince Therapeutics announces last visit from last patient in NEAT trial
- Quince Therapeutics publishes summary of early-stage clinical studies of eDSP
- Promising Outlook for Quince Therapeutics: Phase 3 Study and Innovative Platform Drive Buy Recommendation
- Quince Therapeutics Reports Q3 2025 Financial Results